US FDA to decide on Santarus ulcerative colitis drug in October
This article was originally published in Scrip
Executive Summary
The US FDA accepted for review Santarus' new drug application (NDA) for Uceris (budesonide) for the induction of remission of mild to moderate active ulcerative colitis, a serious, chronic disease that produces inflammation and ulcers along the inside of the colon and affects an estimated 1.4 million Americans.